

Oncology Today with Dr Neil Love: Key Presentations on the Treatment of Multiple Myeloma from the 2020 ASH Annual Meeting

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. The Phase I CRB-402 study is evaluating which of the following strategies in combination with anti-B-cell maturation antigen (anti-BCMA) chimeric antigen receptor T-cell therapy to enrich the drug product for memory-like T cells in patients with relapsed/refractory multiple myeloma (MM)?**
 - Immune checkpoint inhibition
 - PI3K inhibition
 - Bcl-2 inhibition
- 2. What was observed in the DREAMM-2 study among patients with heavily pretreated MM (≥ 7 prior lines of therapy) who received the antibody-drug conjugate belantamab mafodotin?**
 - Short duration of response (<5 months)
 - A low overall response rate (<20%)
 - Manageable ocular toxicities
- 3. Which of the following strategies is effective in preventing or mitigating the side effects associated with selinexor in the treatment of MM?**
 - Antiemetic medication
 - Adequate hydration
 - Salt supplementation
 - All of the above
- 4. Which of the following drug types best describes the mechanism of action of the novel agent iberdomide?**
 - Anti-CD38 antibody
 - Bcl-2 inhibitor
 - BCMA-targeted agent
 - "CELMod" (cereblon E3 ligase modulator)